These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16731764)

  • 1. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
    Buggy JJ; Cao ZA; Bass KE; Verner E; Balasubramanian S; Liu L; Schultz BE; Young PR; Dalrymple SA
    Mol Cancer Ther; 2006 May; 5(5):1309-17. PubMed ID: 16731764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
    Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
    Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
    Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
    Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
    Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
    Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
    Kato Y; Salumbides BC; Wang XF; Qian DZ; Williams S; Wei Y; Sanni TB; Atadja P; Pili R
    Mol Cancer Ther; 2007 Jan; 6(1):70-81. PubMed ID: 17237267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
    Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
    Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.
    Myzak MC; Karplus PA; Chung FL; Dashwood RH
    Cancer Res; 2004 Aug; 64(16):5767-74. PubMed ID: 15313918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
    Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
    Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor.
    Kong Y; Jung M; Wang K; Grindrod S; Velena A; Lee SA; Dakshanamurthy S; Yang Y; Miessau M; Zheng C; Dritschilo A; Brown ML
    Mol Cancer Ther; 2011 Sep; 10(9):1591-9. PubMed ID: 21697394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.
    Huang HL; Lee HY; Tsai AC; Peng CY; Lai MJ; Wang JC; Pan SL; Teng CM; Liou JP
    PLoS One; 2012; 7(8):e43645. PubMed ID: 22928010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
    Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
    Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
    Pidugu VR; Yarla NS; Bishayee A; Kalle AM; Satya AK
    Apoptosis; 2017 Nov; 22(11):1394-1403. PubMed ID: 28840369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of a novel sulfur-containing hydroxamate histone deacetylase inhibitor H40.
    Long J; Zhao J; Yan Z; Liu Z; Wang N
    Int J Cancer; 2009 Mar; 124(5):1235-44. PubMed ID: 19058176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential protein acetylation induced by novel histone deacetylase inhibitors.
    Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
    Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.
    Huang H; Liu N; Yang C; Liao S; Guo H; Zhao K; Li X; Liu S; Guan L; Liu C; Xu L; Zhang C; Song W; Li B; Tang P; Dou QP; Liu J
    PLoS One; 2012; 7(12):e52576. PubMed ID: 23285100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.